-+ 0.00%
-+ 0.00%
-+ 0.00%

DiaMedica Therapeutics Insiders Land Bargain With Gains Of US$2.1m

Simply Wall St·11/17/2026 11:18:08
Listen to the news

Insiders who bought DiaMedica Therapeutics Inc. (NASDAQ:DMAC) in the last 12 months may probably not pay attention to the stock's recent 14% drop. After accounting for the recent loss, the US$14.0m worth of shares they purchased is now worth US$16.1m, suggesting a good return on their investment.

While insider transactions are not the most important thing when it comes to long-term investing, logic dictates you should pay some attention to whether insiders are buying or selling shares.

DiaMedica Therapeutics Insider Transactions Over The Last Year

In the last twelve months, the biggest single purchase by an insider was when insider Jan Stahlberg bought US$7.6m worth of shares at a price of US$8.57 per share. That means that even when the share price was higher than US$8.33 (the recent price), an insider wanted to purchase shares. While their view may have changed since the purchase was made, this does at least suggest they have had confidence in the company's future. To us, it's very important to consider the price insiders pay for shares. It is encouraging to see an insider paid above the current price for shares, as it suggests they saw value, even at higher levels. Jan Stahlberg was the only individual insider to buy during the last year.

Jan Stahlberg purchased 1.94m shares over the year. The average price per share was US$7.26. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. By clicking on the graph below, you can see the precise details of each insider transaction!

See our latest analysis for DiaMedica Therapeutics

insider-trading-volume
NasdaqCM:DMAC Insider Trading Volume November 17th 2026

There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of undervalued small cap companies that insiders are buying.

Insider Ownership Of DiaMedica Therapeutics

Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. We usually like to see fairly high levels of insider ownership. It's great to see that DiaMedica Therapeutics insiders own 47% of the company, worth about US$221m. I like to see this level of insider ownership, because it increases the chances that management are thinking about the best interests of shareholders.

What Might The Insider Transactions At DiaMedica Therapeutics Tell Us?

There haven't been any insider transactions in the last three months -- that doesn't mean much. On a brighter note, the transactions over the last year are encouraging. It would be great to see more insider buying, but overall it seems like DiaMedica Therapeutics insiders are reasonably well aligned (owning significant chunk of the company's shares) and optimistic for the future. So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. For instance, we've identified 4 warning signs for DiaMedica Therapeutics (3 are concerning) you should be aware of.

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.